Working together to make the healthcare system better.
The members of Interpharma have elected Katrien De Vos, AstraZeneca’s Country President for Switzerland, Chair of its Executive Committee. In this function she intends to advocate a stronger dialogue and closer collaboration between the actors in the healthcare system. Her aim is to create a sustainable and resilient Swiss healthcare system.
Katrien De Vos is pleased to be elected Chair of the Executive Committee: “I feel honoured
to take on this responsible task and to represent the views of the research industry in the health policy debate. To enable us to present long-term sustainable and acceptable solutions, it is crucially important for all actors in the healthcare system to work more closely together once again. I will work with great commitment to achieve this.”
Katrien De Vos has been working for AstraZeneca in various national and international roles for more than ten years. She has been AstraZeneca’s Country President for Switzerland since 2020. She has a doctorate in Applied Physics for Personalised Diagnostics from the University of Ghent and a diploma in business administration from the Vlerick Business School. She lives with her wife and their two children in Zug. She enjoys spending her leisure time hiking or on ski tours in the Swiss mountains.
Contact
Daniel Widrig, Corporate Affairs Director
+41 (0) 41 725 75 75; Media.Switzerland@astrazeneca.com
Further information
Interpharma
Interpharma is the association for research-based pharmaceutical companies in Switzerland and was founded in 1933 with its headquarters in Basel. From a historical point of view, Interpharma was a creation of the major research-based pharmaceutical companies in Switzerland. Following its growth over the past years and the associated sharp increase in its membership, which today includes 23 research-based pharmaceutical companies, Interpharma has become the umbrella association for research-based pharmaceutical companies in Switzerland. Its broad support throughout Switzerland strengthens the position of Interpharma and its commitment to Switzerland’s international competitiveness as a location for research and pharmaceutical development. Interpharma works closely together with all those involved in the Swiss healthcare system and with international organisations, particularly those representing the interests of the research-based pharmaceutical industry in Switzerland and abroad.
Find out more at: www.interpharma.ch
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on research, development and the commercialisation of prescription medications. Its most important therapeutic areas are oncology, biopharmaceuticals (for the treatment of cardiovascular, renal, metabolic, and respiratory disorders and in immunology), and rare diseases. AstraZeneca is based in Cambridge, UK, and operates in over 100 countries.
AstraZeneca in Switzerland
In Switzerland, 350 employees are responsible for coordinating local and international business operations. The most important therapeutic areas are oncology, biopharmaceuticals (for the treatment of cardiovascular, renal, metabolic, and respiratory disorders and in immunology), and rare diseases. To reach climate goals ahead of schedule, AstraZeneca is working tirelessly to reduce CO2 emissions and waste. With its “Ambition Zero Carbon” strategy, the company has set itself the goal of carbon-free business operations. In 2021, AstraZeneca Switzerland was rated by its employees for the fourth time in a row as an outstanding employer and honoured with outside certification as a “Great Place to Work®”.
Find out more at: www.astrazeneca.ch